API developer and manufacturer HAS Healthcare Advanced Synthesis has announced its plans to acquire Cerbios Pharma.
HAS's acquisition of the Swiss-based global chemical and biological API manufacturer will be supported by 65 Equity Partners — meaning the equity company will obtain 40% of Cerbios' shares.
Together, HAS and Cerbios will serve the pharmaceutical industry, joining forces to offer their expertise, technical knowledge and services as an integrated contract development and manufacturing organisation (CDMO).
HAS's decision to acquire Cerbios follows the increase in demand for complex therapies, with innovation occurring in all facets of drug development — from oncology to neurology and rare diseases.
"By merging complementary skills and resources, we can provide our clients with personalised and high-quality solutions — further enhancing our capacity to meet market demands. This transaction will also strengthen the reputation of Ticino on a global level," he said.
"We're delighted to partner with the Braglia family, allowing us to bring together two complementary businesses in a fast-growing industry," added Pascal Heberling, Partner and Co-Head of Europe, 65 Equity Partners.
"This is a transaction that has been planned for a long time to create an internationally important chemical-pharmaceutical hub in Ticino. With the differentiated pipelines and clients of both companies, we will reach new milestones together and further improve the quality of the services offered to our clients," added Waldo Mossi, CEO of HAS Healthcare Advanced Synthesis.
"We are proud to join HAS Healthcare Advanced Synthesis SA and to significantly contribute to the strength and growth of the new Group. HAS represents the ideal partner to help us accelerate our growth and expand our range of offerings and the value we provide to our clients," adds Christian Suà, CEO of Cerbios Pharma.